Khan Junaid H, Green Emily A, Chang Jimmin, Ayala Alexandria M, Barkin Marilyn S, Reinys Emily E, Stanton Jeffrey, Stanten Russell D
Sutter Health Alta Bates Summit Medical Center, Oakland, California.
J Extra Corpor Technol. 2017 Dec;49(4):273-282.
Blood product usage is a quality outcome for patients undergoing cardiac surgery. To address an increase in blood product usage since the discontinuation of aprotinin, blood conservation strategies were initiated at a tertiary hospital in Oakland, CA. Improving transfusion rates for open heart surgery patients requiring Cardiopulmonary bypass (CPB) involved multiple departments in coordination. Specific changes to conserve blood product usage included advanced CPB technology upgrades, and precise individualized heparin dose response titration assay for heparin and protamine management. Retrospective analysis of blood product usage pre-implementation, post-CPB changes and post-Hemostasis Management System (HMS) implementation was done to determine the effectiveness of the blood conservation strategies. Statistically significant decrease in packed red blood cells, fresh frozen plasma, cryoprecipitate, and platelet usage over the stepped implementation of both technologies was observed. New oxygenator and centrifugal pump technologies reduced active circuitry volume and caused less damage to blood cells. Individualizing heparin and protamine dosing to a patient using the HMS led to transfusion reductions as well. Overall trends toward reductions in hospital length of stay and intensive care unit stay, and as a result, blood product cost and total hospitalization cost are positive over the period of implementation of both CPB circuit changes and HMS implementation. Although they are multifactorial in nature, these trends provide positive enforcement to the changes implemented.
血液制品的使用情况是心脏手术患者的一项质量指标。为应对自抑肽酶停用以来血液制品使用量的增加,加利福尼亚州奥克兰市的一家三级医院启动了血液保护策略。提高需要体外循环(CPB)的心脏直视手术患者的输血率需要多个部门协同合作。为节省血液制品使用量而采取的具体措施包括升级先进的CPB技术,以及针对肝素和鱼精蛋白管理进行精确的个体化肝素剂量反应滴定测定。对实施前、CPB改变后以及止血管理系统(HMS)实施后的血液制品使用情况进行回顾性分析,以确定血液保护策略的有效性。在逐步实施这两种技术的过程中,观察到红细胞压积、新鲜冰冻血浆、冷沉淀和血小板的使用量有统计学意义的下降。新型氧合器和离心泵技术减少了有效循环血量,对血细胞的损伤也较小。使用HMS对患者进行肝素和鱼精蛋白的个体化给药也导致了输血减少。在实施CPB回路改变和HMS的期间,住院时间和重症监护病房停留时间总体呈下降趋势,因此血液制品成本和总住院成本也呈下降趋势。尽管这些趋势本质上是多因素的,但它们为所实施的变革提供了积极的支持。